Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07267221
Recruiting Phase 1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

NCT07267221 · tracked via the Priya Life Science South Korea tracker
Sponsor
Daewoong Pharmaceutical Co. LTD
Phase
Phase 1
Started
2025-12-01
Last updated
2025-12-05

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

DWJ1622 →DWC202313, DWC202314 →

DWJ1622: DWJ1622 (single oral dose) is administered in accordance with the study protocol.

DWC202313, DWC202314: DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.

Study summary

This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Over 19 year old * Healthy adult volunteers Exclusion Criteria: * with a history of mental disorder * For female volunteers, those who are suspected of being pregnant or lactating

Primary outcome measure(s)

  • Cmax — At pre-dose (0 hours), and post-dose 1 to 72 hours.
    Cmax of DWJ1622 and DWC202313, DWC202314
  • AUClast — Time Frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
    AUClast of DWJ1622 and DWC202313, DWC202314

Trial sites (1)

FacilityCityRegionStatus
H Plus YANGJI Hospital Seoul Gwanak-gu Recruiting

More Daewoong Pharmaceutical Co. LTD. trials in South Korea

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients Starting soon
Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study Starting soon
A Study to Evaluate the Efficacy and Safety of CREZET Tablet Active, not recruiting
To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus Starting soon
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions Recruiting

Other trials for the same condition

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants Starting soon
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions Recruiting
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07267221 on ClinicalTrials.gov ↗ ← All trials in South Korea